High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register

Elisa Gremese, Florenzo Iannone, Gaia Gallo, Piercarlo Sarzi-Puttini, Costantino Botsios, Francesco Trotta, Stefania Gasperini, Mauro Galeazzi, Silvano Adami, Fabrizio Cantini, Marco Sebastiani, Roberto Gorla, Antonio Marchesoni, Annarita Giardina, Rosario Foti, Angiola Mele, Eleonora Bruschi, Gianluca Bagnato, Gian Luca Erre, Giovanni LapadulaCrescenzio Scioscia, Anna Laura Fedele, Gianfranco Ferraccioli, Fabiola Atzeni, Sara Bongiovanni, Leonardo Punzi, Livio Bernardi, Valentina Bagnari, Marcello Govoni, Walter Grassi, Fausto Salaffi, Stefania Manganelli, Elena Frati, Antonio Carletto, Cristian Caimmi, Alice Palloni, Laura Niccoli, Clodoveo Ferri, Ennio Giulio Favalli, Giovanni Triolo, Marcella Di Gangi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Abstract

The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis (RA) patients with moderate or severe disease activity. We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides (GISEA) to investigate the rate of disease remission and functional improvement, based on the 28-Joint Disease Activity Score (DAS28) and the (Health Assessment Questionnaire (HAQ) score in RA patients with moderate or severe disease activity beginning etanercept therapy. Disease was defined as severe (H-RA) with DAS28 ≥5.1 and moderate (M-RA) with DAS28 ≥3.2 to 5.1 at baseline. Patients were considered in remission if DAS28 was ≤2.6, and HAQ ≤0.5 defined normal function. We enrolled 953 RA patients, 320 with M-RA and 633 H-RA. Age and disease duration were similar in the two cohorts, but H-RA patients had significantly more comorbidities (p < 0.01) and took significantly more disease-modifying antirheumatic drugs (p < 0.001) than M-RA patients. After 1 year, the percentage of patients achieving disease remission and normal function (DAS28 ≤2.6 plus HAQ ≤0.5) was higher in M-RA (21.4 %) than in H-RA patients (14.8 %, p = 0.007), regardless of the disease duration. Additionally, female gender (p = 0.006) and H-RA class (p = 0.002) negatively predicted disease remission at 1 year. However, the drug survival rate did not differ between the two subsets. This study confirms that etanercept was effective in the treatment of active RA, but best response, in terms of disease remission and normal function ability, was greater and easier to attain in M-RA patients. These findings may aid clinicians to choose the best strategy to treat RA.
Lingua originaleEnglish
pagine (da-a)31-37
Numero di pagine7
RivistaCLINICAL RHEUMATOLOGY
Volume33
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • remission
  • rheumatoid artritis

Fingerprint

Entra nei temi di ricerca di 'High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register'. Insieme formano una fingerprint unica.

Cita questo